Thermo Fisher Scientific, Inc. vs Eli Lilly & Co.
TMO vs LLY — side-by-side comparison from reported financials. TMO leads 2, LLY leads 9 of 11 comparable metrics.
Thermo Fisher Scientific, Inc.
TMO · Healthcare
$658.02+0.93%Mixed
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | TMO | LLY |
|---|---|---|
| Price | $658.02 | $1 177.20 |
| Market cap | $243B | $1.05T |
| Revenue (TTM) | $46.3B | $79.7B |
| Revenue growth | -0.3% | +31.7% |
| Net margin | 15.0% | 33.5% |
| Free cash flow | $7.32B | $18.2B |
| Net cash (debt) | ($29.3B) | ($35.2B) |
| 1-year price return | +23.1% | +37.6% |
| P/E | 34.9 | 41.6 |
| P/E vs own history (cheap-side %) | 24% | 88% |
| Dividend yield | 0.27% | 0.52% |
| Return on equity | 13% | 93% |
| Altman Z-score | — | 7.10 |
| CV checks passed | 10 of 11 | 11 of 11 |
| Employees | 125,000 | 50,000 |
Full résumé-style profiles: TMO CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.